Beijing, Aug 26, 2026 — China’s National Medical Products Administration (NMPA) suspended the import, sale, and use of ophthalmic surgical blades from Laurus Optics Limited after a remote inspection uncovered severe quality management system deficiencies, marking the second foreign device enforcement action within a week as regulators intensify overseas oversight.

Regulatory Snapshot

Attribute	Detail
Issuer	National Medical Products Administration (NMPA)
Announcement	2026 No. 82
Target company	Laurus Optics Limited (亚伦光学仪器有限公司)
Product	Ophthalmic Surgical Blades
Registration No.	国械注许20252160016
Inspection type	Remote inspection
Effective date	Aug 26, 2026
Legal basis	Medical Device Supervision and Administration Regulations; Medical Device Production Supervision and Administration Measures
Scope of suspension	Import, distribution, and clinical use

Violation Details

The NMPA said its remote review found that Laurus Optics’ quality management system suffered serious deficiencies across critical functions, including key personnel responsibilities, design and development controls, production management, quality control, and product release procedures. Regulators concluded that the lapses created material safety hazards in the finished ophthalmic surgical blades, prompting an immediate market ban to protect public health.

Market Impact Analysis

The suspension halts all commercial activity for Laurus Optics’ sole NMPA-registered device in China, cutting off a supply channel for ophthalmic surgical instruments used in cataract and corneal procedures. The registration prefix “国械注许” indicates the product was approved under the mainland’s special administrative mechanism for Hong Kong, Macau, and Taiwan-registered manufacturers, a category that has faced heightened scrutiny as Beijing tightens quality parity standards across all imported devices.

For Chinese hospitals and distributors, the ban creates an urgent sourcing gap in the ophthalmic blade segment, likely shifting demand to domestic manufacturers or alternative international suppliers with intact NMPA registrations. The enforcement action, announced just one day after the suspension of Avinger peripheral vascular devices, signals a sustained regulatory campaign against foreign manufacturers with quality-system failures rather than isolated product defects.

Forward-Looking Statement

Industry analysts expect Laurus Optics to face a protracted remediation cycle requiring comprehensive quality system overhauls, third-party audits, and a rescheduled NMPA inspection before reinstatement is considered. The back-to-back enforcement actions against foreign device makers in late August suggest regulators are deploying remote inspection capabilities at scale to scrutinize overseas manufacturing sites without the logistical burden of on-site visits. Companies with “国械注许” registrations—particularly smaller specialty instrument firms—should treat this case as a warning to audit their China-facing quality documentation and personnel qualification records proactively. The suspension is likely to remain in place through at least the first quarter of 2027, barring an unusually rapid corrective action submission.-China Health Reform Pulse

Policy Source: https://www.nmpa.gov.cn/ylqx/ylqxggtg/20260827103916159.html

Beijing, Aug 25, 2026 — China’s National Medical Products Administration (NMPA) suspended the import, sale, and use of three medical devices from U.S.-based Avinger, Inc. after the company failed to submit required documentation for an overseas inspection, marking a rare enforcement action against a foreign manufacturer for procedural non-compliance.

Regulatory Snapshot

Attribute	Detail
Issuer	National Medical Products Administration (NMPA)
Announcement	2026 No. 80
Target company	Avinger, Inc. (United States)
Effective date	Aug 25, 2026
Legal basis	Provisions for Overseas Inspections of Drugs and Medical Devices, Article 28; Medical Device Supervision and Administration Regulations
Violation	Failure to submit power of attorney, product information forms, and site master files within required timeframe
Finding	Non-compliance with China’s Medical Device Production Quality Management Specification (GMP)

Affected Products

Product	Registration No.	Description
Pantheris Catheter	国械注进20263010082	Single-use peripheral vascular plaque resection catheter
Pantheris SV Catheter	国械注进20253010610	Single-use peripheral vascular plaque resection catheter
Lightbox 3 OCT Imaging Console	国械注进20263010131	Intravascular optical coherence tomography and power control device

Enforcement Rationale

Under the NMPA’s 2026 overseas inspection plan, regulators scheduled an on-site review of Avinger’s manufacturing and quality systems. Avinger did not provide the mandated authorization letter, product status documentation, or site master file within the stipulated deadline. Pursuant to Article 28 of the overseas inspection regulations, the NMPA classified the deficiency as a failure to meet China’s medical device GMP standards, triggering an immediate suspension of all commercial activities for the three registered products.

Market Impact Analysis

The suspension halts Avinger’s commercial access to China’s market for its peripheral vascular and intravascular imaging portfolio. The Pantheris catheter line, used in peripheral artery disease interventions, and the Lightbox 3 OCT console, used for real-time intravascular imaging, are now barred from importation, distribution, and clinical use nationwide. For Chinese hospitals and distributors, the ban creates an immediate supply gap in peripheral atherectomy and OCT-guided vascular procedures, potentially shifting demand to competing devices from domestic or other international manufacturers.

The enforcement signals heightened NMPA willingness to invoke suspension powers for procedural lapses, not just product quality failures. By acting on documentation deficiencies rather than clinical adverse events, regulators are raising the compliance bar for foreign manufacturers navigating China’s overseas inspection regime.

Forward-Looking Statement

Industry analysts expect Avinger to face a lengthy reinstatement process requiring full documentation submission, followed by a rescheduled inspection and potential corrective action verification. The case is likely to prompt other U.S. and European device makers to audit their China regulatory file readiness, particularly authorization letters and site master files, ahead of scheduled 2026 overseas inspections. With Beijing intensifying scrutiny of imported medical devices, manufacturers with pending NMPA registrations should treat documentation compliance as a critical path item to avoid similar market access disruptions.-China Health Reform Pulse

Policy Source: https://www.nmpa.gov.cn/ylqx/ylqxggtg/20260825165610199.html

China’s National Medical Products Administration (NMPA) announced on April 15 that it has suspended the import, sale, and use of artificial intraocular lenses produced by Indonesia’s Rohto Laboratories due to significant quality and safety concerns.

Policy Breakdown

• Deficiencies Identified: During a remote inspection, the NMPA found severe flaws in the company’s quality management system, particularly in change control, product testing, and validation processes.
• Regulatory Basis: The decision aligns with the Medical Device Supervision and Administration Regulations and the Medical Device Production Supervision and Administration Measures.
• Public Safety Priority: The move underscores China’s commitment to safeguarding public health amid increasing medical device scrutiny.

Market Implications
The suspension could disrupt supply chains for intraocular lenses, a critical component in cataract surgeries. Analysts at China Healthcare Market Research suggest that domestic producers and alternative international suppliers may see short-term demand increases.

Industry Impact
This serves as a warning to medical device manufacturers on the importance of adhering to China’s stringent quality standards. Companies are urged to strengthen quality management systems to avoid similar restrictions.

Looking Ahead
Stakeholders should monitor whether the suspension prompts broader quality audits of imported medical devices. The incident highlights the need for robust compliance strategies in China’s medical device market.-China Health Reform Pulse

Policy Source: https://www.nmpa.gov.cn/ylqx/ylqxggtg/20250417153039134.html